EA200970875A1 - Производные индолизинуксусной кислоты в качестве антагонистов crth2 - Google Patents

Производные индолизинуксусной кислоты в качестве антагонистов crth2

Info

Publication number
EA200970875A1
EA200970875A1 EA200970875A EA200970875A EA200970875A1 EA 200970875 A1 EA200970875 A1 EA 200970875A1 EA 200970875 A EA200970875 A EA 200970875A EA 200970875 A EA200970875 A EA 200970875A EA 200970875 A1 EA200970875 A1 EA 200970875A1
Authority
EA
Eurasian Patent Office
Prior art keywords
acid
cyano
acetic acid
chloro
crth2
Prior art date
Application number
EA200970875A
Other languages
English (en)
Inventor
Джордж Хайнд
Николас Чарльз Рэй
Гарри Финч
Джон Гарри Монтана
Майкл Колин Крамп
Тревор Кейт Гаррисон
Роза Ариэнцо
Пол Блэйни
Янн Гриффон
Дэвид Мидлмисс
Original Assignee
Арджента Орал Терапьютикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арджента Орал Терапьютикс Лимитед filed Critical Арджента Орал Терапьютикс Лимитед
Publication of EA200970875A1 publication Critical patent/EA200970875A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Конкретные перечисленные соединения {7-циано-2-метил-1-[4-(морфолин-4-сульфонил)бензил]индолизин-3-ил}уксусная кислота, [1-(3-хлор-4-этансульфонилбензил)-7-циано-2-метилиндолизин-3-ил]уксусная кислота, {1-[3-хлор-4-(морфолин-4-сульфонил)бензил]-7-циано-2-метилиндолизин-3-ил}уксусная кислота, [1-(3-хлор-4-этансульфонилфенилсульфанил)-7-циано-2-метилиндолизин-3-ил]уксусная кислота, {1-[3-хлор-4-(морфолин-4-сульфонил)фенилсульфанил]-7-циано-2-метилиндолизин-3-ил}уксусная кислота, [7-циано-1-(6-фторхинолин-2-илметил)-2-метилиндолизин-3-ил]уксусная кислота являются лигандами рецептора CRTH2 и полезны в лечении респираторных заболеваний.
EA200970875A 2007-03-21 2007-03-21 Производные индолизинуксусной кислоты в качестве антагонистов crth2 EA200970875A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2007/000996 WO2008113965A1 (en) 2007-03-21 2007-03-21 Indolizine acetic acid derivatives as crth2 antagonists

Publications (1)

Publication Number Publication Date
EA200970875A1 true EA200970875A1 (ru) 2010-04-30

Family

ID=38436764

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970875A EA200970875A1 (ru) 2007-03-21 2007-03-21 Производные индолизинуксусной кислоты в качестве антагонистов crth2

Country Status (12)

Country Link
US (1) US20100137300A1 (ru)
EP (1) EP2136804A1 (ru)
JP (1) JP2010522149A (ru)
CN (1) CN101678009A (ru)
AU (1) AU2007349641A1 (ru)
BR (1) BRPI0721477A2 (ru)
CA (1) CA2681409A1 (ru)
EA (1) EA200970875A1 (ru)
IL (1) IL201090A0 (ru)
MX (1) MX2009010068A (ru)
NO (1) NO20093039L (ru)
WO (1) WO2008113965A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0719485D0 (en) * 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
MX2010006341A (es) 2007-12-14 2010-08-02 Pulmagen Therapeutics Asthma L Indoles y su uso terapeutico.
MX2012010820A (es) 2010-03-22 2012-10-10 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroaril-amino)-1, 2, 3, 4-tetrahidro-9h-carbazo l y sus uso como moduladores del receptor de prostaglandina d2.
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
HUE028972T2 (en) 2011-04-14 2017-01-30 Actelion Pharmaceuticals Ltd 7- (Heteroarylamino) -6,7,8,9-tetrahydropyrido [1,2-a] indole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2015140684A1 (en) 2014-03-17 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP3350179B1 (en) 2015-09-15 2021-01-13 Idorsia Pharmaceuticals Ltd Crystalline forms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES421284A1 (es) * 1973-12-07 1976-04-16 Farmasimes S A Procedimiento para la preparacion de derivados de acidos pirrocolinaceticos.
SE0201635D0 (sv) * 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
GB2407318A (en) * 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB0512944D0 (en) * 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
GB0518783D0 (en) * 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds

Also Published As

Publication number Publication date
JP2010522149A (ja) 2010-07-01
AU2007349641A1 (en) 2008-09-25
CN101678009A (zh) 2010-03-24
CA2681409A1 (en) 2008-09-25
BRPI0721477A2 (pt) 2013-01-15
EP2136804A1 (en) 2009-12-30
US20100137300A1 (en) 2010-06-03
WO2008113965A1 (en) 2008-09-25
MX2009010068A (es) 2010-02-24
NO20093039L (no) 2009-11-17
IL201090A0 (en) 2010-05-17

Similar Documents

Publication Publication Date Title
EA200970875A1 (ru) Производные индолизинуксусной кислоты в качестве антагонистов crth2
LTPA2020534I1 (lt) 1-((5-Heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamido dariniai, kaip fosfatidilinozitolio 3-kinazės (PI3K) inhibitoriai, naudingi proliferacinių ligų gydyme
ATE447559T1 (de) 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen
BR112012017123A2 (pt) composto de n-(1h-indazol-4-il)imidazo [1,2-a]piridina-3-carboxamida como inibidores de cfms
CY1123426T1 (el) Μεθοδος για τη ληψη κρυσταλλων αλατος μεγλουμινης του 1-(5,6-διχλωρο-1η-βενζο[d]ιμιδαζολ-2-υλο)-1η-πυραζολο-4-καρβοξυλικου οξεος
MX2009006795A (es) Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.
CY1112646T1 (el) Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1α
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
EA200971077A1 (ru) Гетероциклические модуляторы киназы
NO20080408L (no) Azaindazolforbindelser og anvendelse derav
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
CY1113642T1 (el) Γεφυρωμενες δικυκλικες ετεροαρυλ υποκατεστημενες τριαζολες, χρησιμες ως αναστολεις της axl
EA200700117A1 (ru) N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
DE602005010970D1 (de) Indol-derivate und ihre verwendung als kinase-hemmer, insbesondere ikk2-hemmer
NO20070293L (no) Aryl-substituerte piperazinderivater
CY1120433T1 (el) Θεραπεια αγωνιστων μελατονινης
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
NO20092694L (no) CRTH2 antagonister
ATE484501T1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
DE602005023124D1 (de) Spirobenzodioxole und deren verwendung als cb1-antagonisten
EA201000486A1 (ru) Ингибитор белка, активирующего 5-липоксигеназу (flap)
UA113658C2 (xx) Кристалічна форма і дималеатного інгібітору тирозинкінази і способи її одержання
NO20080445L (no) Nye azetidinderivater som neurokininreseptorantagonister for behandling av gastrointestinale sykdommer
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
ATE492283T1 (de) Trialkylsilylbenzylaminocarboxyindole, indazole und indoline und ihre verwendung zur behandlung von cetp-vermittelten erkrankungen